Philadelphia, PA – According to filings with the U.S. Securities and Exchange Commission, Interius BioTherapeutics is raising $76,344,951.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Philip Johnson played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Interius BioTherapeutics

Interius BioTherapeutics is an early-stage biotechnology company expanding the potential of cell and gene therapy by developing next generation delivery technology based on inventions from the laboratory of Dr. Saar Gill at the University of Pennsylvania. Our lead programs are initially focused on treating hematologic malignancies by leveraging the Interius platform to generate chimeric antigen receptor (CAR) T cells directly in vivo. Our unique therapeutic approach bypasses the need for ex vivo cell manipulations and the potentially toxic pre-conditioning chemotherapy required for standard CAR T-cell treatments. We are also developing applications beyond immuno-oncology that address diseases not amenable to current gene therapy modalities.

To learn more about Interius BioTherapeutics, visit http://interiusbio.com/

Contact:
Philip Johnson, Chief Executive Officer
215-608-9333
https://www.linkedin.com/in/philip-r-johnson-md-484484114/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved